NEW YORK, NY / ACCESSWIRE / August 10, 2017 / It wasn't Achillion's financial results for the second quarter that had traders jumping on Wednesday, but an update on the company's ACH-4471 trial. ACH-4471, which is intended to treat a rare disease called PNH, produced improvements in four patients who are in the trial. Shares of ACADIA also soared to a four month high yesterday after reporting favorable second quarter earnings.

RDI Initiates Coverage on:

Achillion Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=ACHN

ACADIA Pharmaceuticals Inc.
https://ub.rdinvesting.com/news/?ticker=ACAD

Achillion Pharmaceuticals, Inc.'s shares skyrocketed yesterday and closed up 19.95% on a little over 25 million shares traded. Average volume for the stock is just under 1.5 million shares. Yesterday's trading action was a considerable change from the stock tumbling 11% just last month. In line financial results as well as positive news on the company's pipeline had investors cheering on Wednesday. The company reported a loss of $22.5 million in the second quarter, or 16 cents per share. This was in line with what the Street expected but was also a larger loss than a year ago. Despite the loss, it was the company's update on ACH-4471, a Factor D inhibitor oral drug that is intended to help treat a rare disease called paroxysmal nocturnal hemoglobinuria, or PNH. PNH is a disease where the immune system attacks and destroys red blood cells. Management revealed that four patients who had been given ACH-4471 had shown "meaningful improvements" in regards to LDH, as well as hemoglobin, fatigue score, and other markers of response. The company is now planning to include more patients in the trial. One treatment in the market that treats PNH is Soliris which belongs to Alexion Pharmaceuticals. In the last quarter, Soliris sales totaled $814 million and saw a growth of 16% year over year.

Access RDI's Achillion Pharmaceuticals, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=ACHN

ACADIA Pharmaceuticals Inc.'s shares closed up 12.42% yesterday with nearly 8 million shares traded. The stock hit a four month high on Wednesday after releasing its second quarter earnings report on Tuesday. Before the release, shares of ACADIA had only seen a gain of 2.4% YTD but with Wednesday's reaction, shares have now up more than 15%. For the period, the pharmaceutical company announced a net loss of $0.55 per share. This was a lot better than the $0.71 net loss that was expected by the Street. Revenue at $30.5 million was also significantly higher than the $19.6 million expected. Another exciting announcement was that the company has conducted its End-of-Phase 2 meeting with the Food and Drug Administration on the Alzheimer's disease psychosis program. Looking ahead, ACADIA has also forecast net sales of $105 to $115 million. The highest revenue target from analysts on Wall Street have called for $107 million. HC Wainright has reiterated a "buy" rating on the stock and a $60 price target.

Access RDI's ACADIA Pharmaceuticals Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=ACAD

Our Actionable Research on Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com